ALFA Finder| Revenue growth | Q4 revenue grew 10% YoY to INR 64 crores. |
|---|---|
| Margins | EBITDA margins stable at 16% for Q4; FY26 margin approx 21%. |
| Demand visibility | Strong demand in Gynaecology and Dermatology therapies. |
| Management confidence | High confidence in 1.5x IPM growth and accelerating FY27 momentum. |
Growth
FY26 Net Profit grew 19% before exceptions. Q4 PAT rose 31% YoY to ₹9cr with 14% margin.
Outlook
Targeting 1.5x Indian Pharma Market growth (approx. 12-15%); ₹40cr buyback and 200% dividend announced.
Risks
Macro risks and execution on new molecules; potential cost pressures from raw materials and packaging via CMOs.
Earnings Call filed with NSE, NSE: JAGSNPHARM. Summary written with AI assistance from the document.
Jagsonpal Pharmaceuticals Ltd: key numbers
- Share price
- ₹216.67
- Market cap
- ₹1,429 Cr
- Revenue (annual)
- ₹287.2 Cr
- Net profit (annual)
- ₹43.08 Cr
- P/E (TTM)
- 31.4×Sector 43.8×
- Promoter holding
- 68.81%-0.24% QoQ
- FII holding
- 2.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jagsonpal Pharmaceuticals Ltd
All →Jagsonpal Pharmaceuticals Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue ₹964 Mn (+29%, Aequitas consolidated); standalone revenue ₹814 Mn (+9.3%), EBITDA margin 22.7%, PAT ₹126 Mn flat. H1 standalone PAT +10.3%.
Jagsonpal Pharmaceuticals Results Update
Jagsonpal reported Q2 FY27 consolidated revenue up 29% to ₹964 Mn, with standalone revenue up 9.3%. Standalone H1 PAT grew 10.3% and cash stood at ₹1,347 Mn.
Jagsonpal Pharmaceuticals Q2 FY27 Results: Net Profit ₹12.6 Cr, Up 0.0% YoY
Jagsonpal Pharmaceuticals Ltd reported revenue from operations of ₹81.4 Cr (+9.3% YoY) and net profit of ₹12.6 Cr (+0.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹12.6 Cr · +0.0% YoY
Jagsonpal Pharmaceuticals Board Meeting Date
Jagsonpal Pharmaceuticals Ltd will hold a Board Meeting on October 28, 2026, to consider and approve the company's unaudited financial results for the quarter ended September 30, 2026.
Jagsonpal Pharmaceuticals Other Announcement
Jagsonpal Pharmaceuticals Ltd filed its quarterly shareholding pattern statement in compliance with SEBI Regulation 31(1)(b).
Jagsonpal Pharmaceuticals Acquisition
Jagsonpal Pharmaceuticals has completed the acquisition of the Wellness Portfolio from Group Pharmaceuticals Limited, following the fulfilment of all conditions precedent in the agreement.
- From
- Group Pharmaceuticals Limited